Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CIBA-GEIGY's LAMPRENE (CLOFAZIMINE) "APPROVABLE"

Executive Summary

CIBA-GEIGY's LAMPRENE (CLOFAZIMINE) "APPROVABLE" status was made by FDA Oct. 31. Lamprene in 50 mg and 100 mg capsule form will be used to treat Hansen's disease (leprosy). The NDA for Lamprene, an orphan drug, was filed June 28, 1985. According to Ciba-Geigy, the firm already markets Lamprene in India and other third world countries. The Centers for Disease Control reports that the incidence of leprosy in the U.S. has increased steadily in the past 20 years. In 1965, there were 96 new Hansen's disease cases diagnosed, 162 new cases in 1975, 223 in 1980, and 290 new cases reported in 1984. The agency attributes the increased incidence largely to immigration of leprosy victims to the U.S.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS011060

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel